CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 84 filers reported holding CTI BIOPHARMA CORP in Q2 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $530,914 | -26.1% | 126,408 | +5.8% | 0.00% | 0.0% |
| Q4 2022 | $717,955 | +212.2% | 119,460 | +202.2% | 0.00% | – |
| Q3 2022 | $230,000 | -2.5% | 39,524 | -0.2% | 0.00% | – |
| Q2 2022 | $236,000 | +210.5% | 39,610 | -49.3% | 0.00% | – |
| Q1 2019 | $76,000 | +33.3% | 78,177 | 0.0% | 0.00% | – |
| Q4 2018 | $57,000 | -66.3% | 78,177 | 0.0% | 0.00% | – |
| Q3 2018 | $169,000 | -56.6% | 78,177 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $389,000 | – | 78,177 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 4,068,191 | $4,719,000 | 9.14% |
| CAXTON CORP | 619,460 | $719,000 | 0.76% |
| BVF INC/IL | 6,929,690 | $8,038,000 | 0.50% |
| NEA Management Company, LLC | 7,140,450 | $8,283,000 | 0.33% |
| Orbimed Advisors | 9,520,600 | $11,044,000 | 0.16% |
| Renaissance Technologies | 2,103,792 | $2,440,000 | 0.00% |
| Paloma Partners Management Co | 30,289 | $35,000 | 0.00% |
| WEDBUSH SECURITIES INC | 12,600 | $15,000 | 0.00% |
| HRT FINANCIAL LP | 19,710 | $22,000 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 33 | $0 | 0.00% |